U.S. FDA Approves Breakthrough Therapy Designation for Merus Petosemtamab in Cancer Treatment
Merus N.V., a company specializing in innovative cancer treatments with its multispecific antibodies (Biclonics® and Triclonics®), has recently received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for its drug petosemtamab.
This designation is a significant step forward for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has not responded to platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 treatments.
The BTD is based on preliminary data from an ongoing phase 1/2 trial that is assessing petosemtamab monotherapy in patients with advanced solid tumors, including those with previously treated recurrent or metastatic HNSCC (NCT03526835).
Merus intends to present updated efficacy, durability, and safety results from this cohort later in 2024.
Breakthrough Therapy Designation is designed to accelerate the development and review of drugs for serious conditions that show potential for substantial improvement over existing therapies.
It offers intensive FDA guidance, a collaborative review process, and priority review to speed up the decision-making.
Other similar designations include Fast Track Designation, which facilitates development and review, Priority Review, which shortens the review period, Accelerated Approval, which allows early market entry based on preliminary evidence, and Orphan Drug Designation, which supports treatments for rare diseases.
These designations are crucial for bringing new therapies to patients more quickly, particularly when current treatments are insufficient or unavailable.
